

DMSO Removal and CD3⁺ Cell Selection from Cryopreserved Apheresis Products Using Novel BACS Technology

Content originally prepared for ThermoGenesis by Dalip Sethi¹, Jillian Miller¹, Zelenia Contreras², John Perea², and Stephen Truong²
¹Cesca Therapeutics, Inc., Rancho Cordova, CA USA; ²ThermoGenesis Corp., Rancho Cordova, CA USA


Introduction

Cancer therapy is a complex and growing field of medicine. With the advent of adoptive immunotherapy, coupled with excellent clinical outcomes in CD19⁺ hematologic malignancies, CAR-T cell therapy has created intense interest within the medical and scientific communities. Although genetic-modification of immune cells is one of the most advanced therapies, the manufacturing process still relies on traditional cell processing techniques. We have previously developed a quick and easy method to remove DMSO from thawed apheresis products and have now coupled this technology with the selection of CD3⁺ T-cells using ThermoGenesis' technology, Buoyancy-Activated Cell Sorting (X-BACS™) process. DMSO removal was successfully achieved using the X-WASH® System.


Materials and Methods

Healthy adult cryopreserved apheresis samples were thawed at 37°C and diluted with thaw-wash media (2.5% HSA, 5% Dextran, and DNase I in saline). The sample was transferred to an X-WASH Disposable Cartridge. Post-centrifugation, waste media was removed using positive pressure, and new media was added using controlled negative pressure. Washed cells were transferred to a new Disposable Cartridge and incubated with anti-CD3 antibody followed by incubation with microbubble reagent. The target and non-target fractions were separated using centrifugation. CD3⁺ cells were also studied for expansion using CD3/CD28 and IL-2 activation.

In a separate experiment, the expansion of CD3⁺ cells isolated using X-BACS was equivalent to CD3⁺ cells isolated using technologies from other manufacturers. Viable CD3⁺ cells were quantified over 14 days using flow cytometry.




Process Flow




Results and Discussion


The DMSO removal from cryopreserved samples and CD3⁺ cell isolation was accomplished in two phases. Each phase was studied for recovery efficiency and cell viability.



To assess the consistency of CD3⁺ cell recoveries using the X-BACS process, the antibody and microbubble concentrations were kept constant while cell concentrations were increased. The results indicate only a marginal drop in CD3⁺ cell recovery within the normally expected dose range (30 to 200 x 10⁶/mL).



Overall recovery was calculated by multiplying values obtained in X-WASH and X-BACS steps. A mean CD3⁺ cell recovery of 81% was observed (n=3).



Conclusions

DMSO removal using the X-WASH System resulted in cell recoveries of greater than 90% with no significant loss of viability. A mean CD3⁺ cell recovery of 84% was accomplished using the X-BACS process with high purity (>94%). In brief, we have developed an efficient method for removing DMSO and isolating CD3⁺ T-cells from cryopreserved apheresis samples that can be used for CAR-T cell manufacturing.